There are currently 31 ongoing clinical trials involving Alport Syndrome
Of the 31 trials,25 trials are in Phase II
Furthermore, 5 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Alport Syndrome, a genetic disorder. Asia-Pacific, North America, and Europe are the regions involved in Alport Syndrome-related drug trials.
Alport Syndrome related clinical trial sponsors
Reata Pharmaceuticals Inc, Shanghai Children's Hospital, Chinook Therapeutics Inc, Travere Therapeutics Inc, and Sanofi are a few notable sponsors involving Alport Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
United States of America
China
United States of America
United States of America
United States of America
Germany
France
Switzerland
United Kingdom
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer